The quest for an effective HIV vaccine has hit a major roadblock, but a groundbreaking study offers a glimmer of hope. The challenge? Tricking the body into producing the right immune cells.
In the intricate world of vaccine development, HIV poses a unique dilemma. Researchers have been grappling with the task of coaxing the immune system to generate specific antibodies and immune cells to combat HIV. Traditionally, vaccines employ a clever tactic: attaching HIV proteins to a larger protein structure that mimics a virus. This triggers the immune system to produce antibodies that recognize various parts of these proteins. But here's the catch: some antibodies react not to HIV, but to the very scaffold used to deliver the vaccine.
And this is where the study gets fascinating. Scientists from Scripps Research and MIT have crafted a novel vaccine scaffolding using DNA, which the immune system conveniently ignores. Published in Science on February 5, 2026, the study reveals that these DNA-based scaffolds led to a tenfold increase in immune cells targeting a critical HIV site compared to protein-based scaffolds. This suggests a more precise and robust immune response to the DNA vaccines.
But here's where it gets controversial:
"It's a game-changer that could pave the way for an HIV vaccine or tackle other complex vaccine puzzles," says senior author Darrell Irvine, a professor at Scripps Research. Typically, vaccines consist of scaffolding particles adorned with numerous inert viral proteins (antigens) that the immune system can identify. These structures, akin to viruses, present multiple copies of antigens on their surface, prompting a stronger immune response than older, less effective vaccines. However, a potential pitfall is that these scaffolds are often made from proteins, which can inadvertently trigger immune reactions to the scaffolds themselves.
For most vaccines targeting common pathogens, this off-target response isn't a significant concern. But for HIV, influenza, and pan-coronavirus vaccines, where broadly protective B cells are exceptionally scarce, every competing immune response matters. The researchers were aware that protein nanoparticle scaffolds elicit their own immune responses, but the extent to which these off-target reactions hindered the desired immune cells was unknown.
The team, including lead author Anna Romanov and biological engineer Mark Bathe from MIT, turned to DNA origami technology, a technique that enables the folding of DNA into precise 3D shapes. While data on DNA origami in vaccines is limited, the scientists knew that B cells, responsible for recognizing antigens and producing antibodies, do not react to DNA. This is partly due to the body's defense mechanism against autoimmune reactions targeting its own DNA.
"Our previous work in 2024 using a SARS-CoV-2 antigen showed that DNA scaffolds were immunologically silent, but we weren't sure if they'd also encourage focused germinal center responses. This study confirms this response for Scripps' HIV antigen, a significant advancement for active immunotherapy," explains Bathe.
The researchers designed DNA nanoparticles capable of displaying 60 copies of an HIV envelope protein known to activate rare B cells, which can produce broadly neutralizing antibodies against HIV. When tested in mice with human antibody genes, nearly 60% of germinal center B cells, specialized cells that produce high-quality antibodies, targeted the HIV envelope protein. In contrast, the protein-scaffolded vaccine, currently in clinical trials, resulted in germinal centers where only 20% of B cells recognized the HIV target, with many cells responding to the scaffold.
The DNA vaccine outperformed the protein scaffold by a remarkable 25-fold in terms of HIV-specific to off-target immune cells. Within two weeks, mice given the DNA vaccine showed detectable levels of the desired rare B cells, while those receiving the protein nanoparticle vaccine had none.
The implications reach beyond HIV, as the same hurdles exist in developing universal influenza and pan-coronavirus vaccines. DNA origami scaffolds could offer a more targeted immune response for these complex vaccine challenges, according to Irvine. He adds, "These vaccines aim to engage incredibly rare B cells, and anything that hinders their activation is a concern. DNA origami scaffolds might be the solution we've been seeking."
The Irvine and Bathe teams are now investigating how DNA origami shape variations affect vaccine efficacy and assessing the scaffolds' long-term safety for vaccination. This study marks a significant step forward in vaccine technology, offering a new approach to tackling some of the most challenging vaccine targets.
What are your thoughts on this innovative approach to vaccine development? Do you think DNA origami scaffolds could be the key to unlocking effective vaccines for HIV and other complex viruses? Share your insights and join the discussion!
